Organogenesis HoldingsFRA:2PQ -2.83%65 Days Payable is 106.50 as of Mar. 2026, which is 1% below its 10-year median of 107.17. GuruFocus rates FRA:2PQ with a GF Score™ of 65/100 and a GF Value™ of €2.68 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Organogenesis Holdings ranks worse than 55.75% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2PQ vs TKNO, AKBA, SIGA: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Organogenesis Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (FRA:2PQ) has a Days Payable of 106.50 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Organogenesis Holdings and its competitors. This is near median its historical median of 107.17. Over the past decade, Organogenesis Holdings' Days Payable has ranged from 80.76 to 114.27. According to the industry distribution chart, Organogenesis Holdings ranks #514 out of 922 companies in the Drug Manufacturers industry, placing it in the top 55.7%.
Is Organogenesis Holdings' Days Payable too high?
Organogenesis Holdings' current Days Payable of 106.50 is near median its 10-year median of 107.17. Over the past 10 years, this metric has ranged from a low of 80.76 to a high of 114.27. The Drug Manufacturers industry median Days Payable is 90.84. Organogenesis Holdings' value of 106.50 is 17.2% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #514 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Days Payable compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #514 out of 922 companies for Days Payable. This places Organogenesis Holdings in the lower half of its industry. The industry median Days Payable is 90.84. Organogenesis Holdings' value of 106.50 is 17.2% above this benchmark. Historically, Organogenesis Holdings' own Days Payable has ranged from 80.76 to 114.27 over the past decade. While the company's 10-year median is 107.17 vs. the industry median of 90.84, Organogenesis Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Days Payable of 106.50 is 17.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Days Payable is 106.50, which is near median its own 10-year median of 107.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.68, compared to a current price of €2.06 — trading 23.1% below its estimated fair value. The current Days Payable is 106.50, which is near median its 10-year median of 107.17 and 17.2% above the Drug Manufacturers industry median of 90.84. Organogenesis Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current Days Payable is 106.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.06 is trading 23.1% below its estimated GF Value™ of €2.68.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for FRA:2PQ:
Days Payable: 106.50 (near median its 10-year median of 107.17)
GF Value™: €2.68 vs. price of €2.06 (23.1% below fair value)
Industry Position: 17.2% above the Drug Manufacturers median (#514 of 922)
No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
65GF Score
Get the complete analysis for FRA:2PQ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2PQ has been successfully added to your 
